Details of the Drug Reposition

General Information of This Drug (ID: DML61S4)

Drug Name
ARQ-151   DML61S4
Drug Type
Small molecular drug

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
1 Phase 3 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Atopic dermatitis DISTCP41 EA80 Phase 3 [1]
------------------------------------------------------------------------------------
1 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Psoriasis vulgaris DIS6M7AN EA90 Phase 2 [2]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT04804605) Open Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (INTEGUMENT-OLE). U.S. National Institutes of Health.
2 ClinicalTrials.gov (NCT04746911) Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Psoriasis (ARQ-151-216). U.S. National Institutes of Health.